Cancer and Immunology · uk
Immune brakes intensify before lung cancer develops: Study finds clues for early interception
Regulatory T cells accumulating around precancerous lesions may offer both a warning signal in blood and an opportunity for intervention. Longitudinal human samples and mouse experiments point to a new direction, but clinical validation is still needed before blood tests can assess risk or drugs can prevent lung cancer.
Before abnormal cells in the lungs become invasive cancer, the surrounding immune environment may already have changed. A University College London (UCL) research team found that a group of cells responsible for suppressing immune responses gradually accumulates months or even years before lung cancer develops. This signal prompted researchers to ask whether the conditions supporting a precancerous lesion’s growth could be changed before it crosses the threshold into malignancy.
The study, led by James Reading and Sam Janes, was published in *Nature* on October 7. The team analyzed blood and tissue from people undergoing follow-up with autofluorescence bronchoscopy or computed tomography, using multi-omic immune profiling to connect changes in local lesions with circulating cells. These samples from surveillance and screening programs offered a window into how the disease develops.
The clues centered on regulatory T cells (Tregs). These cells normally suppress the activity of other immune cells. The study found that effector Tregs expressing the transcription factor BATF increased in high-grade precancerous airway lesions and were clonally related to the same type of cells in blood. This supports the existence of an immune network spanning tissue and blood that may contribute to precancerous lesions escaping immune control.
As precancerous changes progressed, effector Tregs in blood also gradually increased. UCL and UK Research and Innovation said the team had used a prototype blood test to track this change, exploring its potential as a risk signal. However, interpreting a single blood test result will still require clarifying interference from factors such as infection or chronic inflammation, as well as validation in larger prospective studies.
The research also moved from monitoring to intervention. In a carcinogen-induced mouse model, inhibiting PI3Kδ signaling reduced Tregs in blood and the lungs, suppressed immature lymphoid aggregates rich in Tregs around the bronchi, and increased local type 1 conventional dendritic cells. According to UCL and UK Research and Innovation, the proportion of animals that developed lung tumors in the experiment was halved, and large tumors no longer occurred.
These results provide a mechanistic basis for “cancer interception”: identifying biological changes that can be monitored and targeted before invasive disease develops. However, the associations in human samples and the results of drug treatment in mice do not yet prove that the same strategy can prevent lung cancer in humans. Particularly because those receiving an intervention may not yet have invasive cancer, safety and the selection of people who could benefit require more rigorous evidence.
The next hurdle for this work is to align blood warning signals with the timing of intervention. The research was funded by Cancer Research UK and the Medical Research Council, with additional support from the National Institute for Health and Care Research and others, and a patient and public involvement group helped shape its direction. Only if subsequent work can establish which immune changes predict worsening disease and who can safely benefit might lung cancer care be able to act even earlier.